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Abstract
Objective: We developed a predictive model for significant fibrosis in chronic hepatitis B (CHB) based on routinely available
clinical parameters.
Methods: 237 treatment-naı¨ve CHB patients [58.4% hepatitis B e antigen (HBeAg)-positive] who had undergone liver biopsy
were randomly divided into two cohorts: training group (n = 108) and validation group (n = 129). Liver histology was
assessed for fibrosis. All common demographics, viral serology, viral load and liver biochemistry were analyzed.
Results: Based on 12 available clinical parameters (age, sex, HBeAg status, HBV DNA, platelet, albumin, bilirubin, ALT, AST,
ALP, GGT and AFP), a model to predict significant liver fibrosis (Ishak fibrosis score $3) was derived using the five best
parameters (age, ALP, AST, AFP and platelet). Using the formula log(index+1) = 0.025+0.0031(age)+0.1483 log(ALP)+0.004
log(AST)+0.0908 log(AFP+1)20.028 log(platelet), the PAPAS (Platelet/Age/Phosphatase/AFP/AST) index predicts significant
fibrosis with an area under the receiving operating characteristics (AUROC) curve of 0.776 [0.797 for patients with ALT
,26upper limit of normal (ULN)] The negative predictive value to exclude significant fibrosis was 88.4%. This predictive
power is superior to other non-invasive models using common parameters, including the AST/platelet/GGT/AFP (APGA)
index, AST/platelet ratio index (APRI), and the FIB-4 index (AUROC of 0.757, 0.708 and 0.723 respectively). Using the PAPAS
index, 67.5% of liver biopsies for patients being considered for treatment with ALT ,26ULN could be avoided.
Conclusion: The PAPAS index can predict and exclude significant fibrosis, and may reduce the need for liver biopsy in CHB
patients.
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Introduction
Up to 40% of patients with chronic hepatitis B (CHB) would
develop cirrhotic complications or hepatocellular carcinoma
(HCC) during their lifetime [1]. While several clinical parameters,
including male gender, older age, higher levels of alanine
aminotransferase (ALT) and serum HBV DNA have been
identified as risk factors for severe liver disease [2,3,4], the golden
standard in assessing disease severity remains to be liver biopsy.
Liver biopsy is still recommended for certain CHB patients,
especially those with an ALT level of ,26upper limit of normal
(ULN) [5,6]. However, up to 2% of patients develop complications
from liver biopsy [7,8]. Others problems like intra-observer
variation and sampling error are also unavoidable [9,10,11].
There is thus an increasing demand for developing predictive
models of fibrosis based on non-invasive markers.
Many predictive models of fibrosis, including the AST/platelet
radio index (APRI) and FIB-4 index, were based on patients with
chronic hepatitis C [12,13,14,15,16,17]. Using such models to
predict liver fibrosis in CHB patients had produced conflicting
results [18,19]. Only a minority of models were based on CHB
patients [20,21,22,23], and these models were limited by a
disproportionate percentage of either hepatitis B e antigen
(HBeAg)-positive or –negative patients. Some of these studies also
lack patients with normal serum ALT [20,21]. A recently-derived
model is the aspartate aminotransferase (AST)/platelet/gamma-
glutamyl transpeptidase (GGT)/a-fetoprotein (AFP) (APGA)
index, but this is limited by its correlation with transient
elastography and not actual liver histology [24]. Another factor
limiting the use of other non-invasive models is that markers used
in prediction may not be routinely available in non-research
laboratories [18,20,25,26].
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The aim of this study is to create a predictive model based on
routinely-available clinical parameters to accurately predict
significant fibrosis in both HBeAg-positive and -negative CHB.
Methods
Patients
The current study included treatment-naı¨ve patients who were
enrolled into therapeutic drug trials between 1994 and 2008 in the
Department of Medicine, the University of Hong Kong, Queen
Mary Hospital. All patients were positive for hepatitis B surface
antigen (HBsAg) for at least 6 months, with a HBV DNA level of
more than 2,000 IU/mL, and a serum ALT of less than 10 times
the ULN prior to recruitment. Patients with decompensated
cirrhosis or concomitant liver disease, including chronic hepatitis
C or D virus infection, primary biliary cirrhosis, autoimmune
hepatitis, Wilson’s disease, and significant intake of alcohol (20
grams per day for female, 30 grams per day for male) were
excluded. Written consent was obtained prior to liver biopsy, and
all trials had been approved by the Institutional Review Board of
the University of Hong Kong.
Patient demographics and laboratory parameters (altogether 12
variables) were recorded at the time of liver biopsy. These include
age, gender, HBeAg status, HBV DNA levels, albumin, bilirubin,
ALT, AST, alkaline phosphatase (ALP), GGT, AFP and platelet
count. The ULN of ALT was based on the respective drug trial,
ranging from 45 to 53 U/L in men and 31 to 43 U/L in women.
Serum HBV DNA levels were measured by three different assays,
as follow: a branched DNA assay (Versant HBV DNA 3.0 assay,
Bayer Health-Care Diagnostic Division, Tarrytown, NY), with a
lower limit of quantification of 400 IU/mL in 33 patients, Cobas
Amplicor HBV Monitor Test (Roche Diagnostic, Branchburg, NJ)
with a lower limit of quantification of 60 IU/mL in 88 patients,
and Cobas Taqman assay (Roche Diagnostic, Branchburg, NJ)
with a lower limit of quantification of 12 IU/mL in 116 patients.
Liver Biopsy
An 18G sheathed cutting needle (Temno Evolution, Cardinal
Health, McGaw Park, IL) was used for liver biopsy for 33 patients,
with a minimum length of 1.5 cm obtained. For the remainder of
the cohort, a 17G core aspiration needle (Hepafix, B. Braun
Melsungen AG, Germany) was used, with a minimum length of
2 cm obtained. Histologic grading of necroinflammation and
staging of liver fibrosis were performed using the Knodell
histologic activity index [27] and Ishak fibrosis score [28]
respectively, by a single histopathologist blinded to the patients’
laboratory data. Significant fibrosis was defined as an Ishak score
of 3 or more, meaning the presence of at least bridging fibrosis.
Statistical analysis
The primary endpoint of the present study was to determine
whether there were associations between significant fibrosis which
were present in 77 patients (32.4%) in the entire cohort, and the 12
routinely-available clinical parameters mentioned above. Data was
randomly divided into a training cohort and a validation cohort.
Concerning the optimal sample size of this study, with 32.4% of
our patient cohort having significant fibrosis and allowing a 10%
error for a 95% confidence interval, 84 patients were needed in
each cohort for the study to be adequately powered. A training
cohort consisting of 108 patients (45.6%) was used to develop the
model. The remaining 129 patients (54.4%) formed the validation
cohort. All statistical analyses were performed using SPSS version
16.0 (SPSS Inc., Chicago, IL), SAS system version 9.1, R version
2.81 and STATA/SE 9.2.
To create a new predictive model, all variables were subjected
to a logarithmic transformation for a better model fit. The
sequence of variables in order of their associations with significant
liver fibrosis (co-efficient path) was determined by L1 regularized
regression. The area under the receiving operating characteristics
(AUROC) curve was determined for each number of variables
used for the prediction of significant fibrosis. The number of
variables used was decided when the addition of extra variables
failed to give a relatively better accuracy. A new predictive model
was then created with the optimal cut-off value determined as the
value with the highest sensitivity and specificity. Using the new
regression model, the AUROC, sensitivity, specificity, positive and
negative predictive values and likelihood ratios were calculated.
This new predictive model was compared to three pre-existing
non-invasive indexes using routinely-available clinical parameters:
the APRI, the FIB-4 index and the APGA index. The APRI was
calculated using [AST (U/L)/(ULN of AST)/platelet count
(6109/L)]6100 [12]. The FIB-4 index was calculated using [age
(years)6AST (U/L)]/{[PLT (109/L)]6(ALT(U/L)]1/2}f [13]. The
APGA index was calculated using log(index) = 1.44+0.1490
log[GGT (U/L)]+0.3308log [AST (U/L)]20.5846log [platelet
count (6109/L)]+0.1148log [AFP (ng/mL)+1] [24].
The Mann-Whitney U test was used for continuous variables
with a skewed distribution; the chi-squared test was used for
categorical variables. Correlation between different predictive
models with significant fibrosis was performed using Spearman
correlation co-efficient. A two-sided p value of ,0.05 was
considered statistically significant.
Results
A total of 237 patients with all 12 clinical parameters available
were recruited. The characteristics of all 237 patients at the time of
liver biopsy, including a comparison between the training and
validation cohorts, are shown in Table 1. The median age was
38.2 years and 98 patients (41.3%) were HBeAg-positive. Twenty-
five patients (10.5%) had a normal ALT level. Significant fibrosis
and cirrhosis were present in 77 patients (32.4%) and 5 patients
(2.1%) respectively. The percentage of patients with significant
fibrosis in patients with ALT $26ULN and ,26ULN were
39.6% (44 out of 111 patients) and 26.2% (33 out of 126 patients)
respectively.
The sequence of variables added at each step under the
AUROC curve is shown in Figure 1. The addition of the first 5
variables (AFP, ALP, age, AST, platelet count) achieved a best fit
in the regression model. The further addition of variables only
increases the complexity of the formula without achieving a
marked improvement in prediction accuracy. Using L1 regular-
ized regression, a new predictive model for significant fibrosis,
named the PAPAS index (Platelet/Age/Phosphatase/AFP/AST),
was derived as follows:
log Indexz1ð Þ~0:0255z0:0031|age yearsð Þz
0:1483|log ALP U=Lð Þ½ gz0:004|
log AST U=Lð Þ½ z0:0908|log AFP ng=mLð Þz1½ {
0:028|log platelet count 109

L
  
:
The AUROC for predicting significant fibrosis was 0.701 for
the training cohort and 0.776 for the validation cohort (Figure 2).
There was no significant difference in the AUCs of both training
and validation groups (p = 0.270). The PAPAS index was then
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compared with three previously published non-invasive indices i.e.
the APRI, the FIB-4 index and the APGA index. The boxplots of
the four indices in predicting significant fibrosis are shown in
Figure 3. APRI, the FIB-4 index, the APGA index and the PAPAS
index all correlated well with significant fibrosis [r = 0.337, 0.338,
0.418 and 0.426 respectively (all p,0.001)]. The AUROC for
predicting significant fibrosis in the validation cohort for all four
models is shown in Figure 4a. The AUC of the PAPAS index,
APGA index, FIB-4 index and APRI were 0.776, 0.758, 0.723 and
0.708 respectively (Table 2). The AUC of the PAPAS index was
significantly better than APRI (p = 0.009). There were no
significant differences between the AUCs of PAPAS index, APGA
index and FIB-4 index. For patients with ALT ,26ULN, the
AUROC for all for indices is shown in Figure 4b. The AUC of the
PAPAS index improved to 0.797 (Table 3). The accuracy and
correlation coefficients of the PAPAS index are the best among the
4 models.
The sensitivity, specificity, predictive values and likelihood
ratios of all four indices are shown in Table 4, using the various
cut-offs suggested for each model. Using an optimal cut-off of
1.662, the PAPAS index had a sensitivity of 73.3% and a
specificity of 78.2% in predicting significant fibrosis. The negative
predictive value was 88.4%.
Table 1. Characteristics of 237 patients included in model.
Total Training Validation p value
Number of patients 237 108 129
Age (years) 38.2 (18–63) 36.4 (18–63) 40.0 (18–61) 0.695
Number of male patients 160 (67.2%) 73 (67.6%) 87 (67.4%) 0.980
Number of HBeAg-positive patients 98 (41.3%) 42 (38.9%) 56 (43.4%) 0.481
Albumin (g/L) 46 (36–54) 46 (37–54) 45 (36–53) 0.156
Bilirubin (umol/L) 12 (3–96) 12 (3–96) 12 (3–31) 0.348
ALP (U/L) 76 (20–242) 73.5 (33–145) 76 (20–242) 0.283
AST (U/L) 54 (16–304) 52 (16–304) 55 (18–304) 0.490
ALT (U/L) 87 (14–507) 80.5 (15–469) 95 (14–507) 0.334
Number of patients with
N Normal ALT 25 (10.5%) 10 (9.3%) 15 (11.6%)
N ALT 1–26ULN 101 (42.6%) 46 (42.6%) 55 (42.6%)
N ALT .26ULN 111 (46.8%) 52 (48.1%) 59 (45.7%)
GGT (U/L) 33 (5–160) 30.5 (6–134) 35 (5–160) 0.999
AFP (ng/mL) 4 (1–178) 4 (1–178) 4 (1–86) 0.420
Platelet (6109/L) 201 (93–334) 206.5 (95–331) 198 (93–334) 0.571
HBV DNA (log IU/mL) 6.77 (2.70–14.0) 6.99 (3.50–11.8) 6.76 (2.70–14.0) 0.148
Number of patients with significant
necroinflammation (NI$7)
120 (50.6%) 47 (43.5%) 73 (56.6%) 0.339
Number of patients with significant fibrosis (F$3) 77 (32.4%) 30 (27.8%) 47 (36.4%) 0.091
N F6 5 (2.1%) 3 (2.8%) 2 (1.6%)
N F5 15 (6.3%) 7 (6.5%) 8 (6.2%)
N F4 25 (10.5%) 13 (12.0%) 12 (9.3%)
N F3 32 (13.5%) 7 (6.5%) 25 (19.4%)
N F2 59 (24.8%) 28 (25.9%) 31 (24.0%)
N F1 71 (29.8%) 32 (29.6%) 39 (30.2%)
N F0 30 (12.6%) 18 (16.7%) 12 (9.3%)
Continuous variables expressed in median (range) F = Ishak Fibrosis Score.
doi:10.1371/journal.pone.0023077.t001
Figure 1. Area under the receiver operating characteristics
(AUROC) curve at each step. Steps 1–12 as listed in their order: AFP,
ALP, age, AST, platelet count, albumin, HBV DNA, GGT, gender, bilirubin,
HBeAg status, ALT.
doi:10.1371/journal.pone.0023077.g001
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One hundred and twenty-six patients (53.2%) among our total
patient cohort had an ALT level of ,26ULN, a patient group in
whom liver biopsies are recommended before considering
treatment. Among this group, 85 patients (67.5%) had a score
less than the optimal cut-off of 1.662, suggesting that these patients
do not have significant fibrosis and liver biopsies could be avoided.
Seventy-five out of these 85 patients (88.2%) had insignificant
fibrosis (Ishak stage 0 to 2) on actual histology. For the remaining
10 patients (11.2%), 5 had stage 3 fibrosis and 5 had stage 4
fibrosis. If the revised ULN of ALT as suggested by Prati et al
(30 U/L for men, 19 U/L for women) [29] was used, 39 patients
would have an ALT level of ,26ULN, of which 30 patients
(76.9%) could avoid liver biopsy by having a score of less than
1.662. Twenty-eight out of these 30 patients (93.3%) had
insignificant fibrosis. For the remaining 2 patients (6.7%), one
had stage 3 fibrosis and another had stage 4 fibrosis.
Discussion
Given the invasiveness of liver biopsy, the development of non-
invasive markers for liver fibrosis has always been an attractive
option, especially since non-invasive markers for fibrosis in CHB
are not well-established. Liver biopsy itself also has its limitations,
thus using the AUROC in evaluating non-invasive markers of
fibrosis could never reach the perfect value of 1.0. In fact, it had
Figure 2. Comparison of receiver operating characteristics
(ROC) curves of training and validation cohorts in predicting
significant fibrosis for the PAPAS index.
doi:10.1371/journal.pone.0023077.g002
Figure 3. Model values based on Ishak fibrosis score. The top and bottom of each box represents the 25th and 75th percentile interval, the line
through the box in the median and the error bars are the 5th and 95th percentile intervals.
doi:10.1371/journal.pone.0023077.g003
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been shown previously that a perfect marker for significant fibrosis
would not even reach an AUROC of 0.90 [30,31], which is the
reason for many previous studies can only obtain an AUROC
range of 0.76–0.88 [30].
The PAPAS index obtained an AUROC of 0.776 for the
prediction of significant fibrosis. The AUROC improves to 0.797
for patients with ALT ,26ULN, the group of patients with liver
biopsy recommended before considering treatment. The sensitivity
and specificity of our model were both equally high at 73.3% and
78.2% respectively, and a high negative predictive value of 88.4%
was achieved at the optimal cut-off value. The AUROC obtained
was superior to other models of fibrosis based on commonly-
available clinical parameters used in our cohort. Two such models,
the FIB-4 index and APRI, were initially created based on patients
with chronic hepatitis C, and therefore might not be suitable for
CHB patients. According to one study, the AUROC of APRI in
218 CHB patients in predicting fibrosis was only 0.63 [19]. Two
other such models based on chronic hepatitis C patients, Fibrotest
and Actitest, achieved satisfactory results in CHB patients, but
were limited by the requirement of using special and non-routinely
available biomarkers. In addition, the majority of the study
population was HBeAg-negative [18]. The disproportionate
representation of either HBeAg-positive or HBeAg-negative
patients was also seen in other non-invasive models for CHB
[20,21,22]. Our study had a good mixture of both HBeAg-positive
(41.3%) and -negative patients, making it more representative of
the whole spectrum of CHB population. Our study also had
patients with different ALT ranges, including a proportion of
patients with normal ALT.
A high negative predictive value meant the predictive model
would excel in excluding CHB patients with significant fibrosis.
For patients with an ALT level of ,26ULN, 67.5% of our cohort
would be able to avoid the invasiveness of a liver biopsy. Among
this subgroup of patients, 88.2% actually had insignificant fibrosis
from histology. While 11.8% (10 out of 85) of patients had a
discordance between the predictive model score and actual
histology, this figure is lower than other studies validating non-
invasive models of liver fibrosis [32,33]. If the revised ULN of
ALT as suggested by Prati et al [29] was used, the percentage of
patients able to avoid liver biopsy would further increase to 76.9%.
Figure 4. Comparison of ROC curves of different predictive models in predicting significant fibrosis for (a) all patients and (b)
patients with ALT ,62 ULN.
doi:10.1371/journal.pone.0023077.g004
Table 2. Area under curve (AUC) of the validation cohort
using the PAPAS index, APGA index, FIB-4 index and APRI for
significant fibrosis in all patients.
AUC for significant fibrosis 95% confidence intervals
PAPAS 0.776 0.694–0.854
APGA 0.757 0.674–0.840
FIB-4 0.723 0.635–0.810
APRI 0.708 0.625–0.800
doi:10.1371/journal.pone.0023077.t002
Table 3. Area under curve (AUC) of the validation cohort
using the PAPAS index, APGA index, FIB-4 index and APRI for
significant fibrosis in patients with ALT ,26ULN.
AUC for significant fibrosis 95% confidence intervals
PAPAS 0.797 0.706–0.888
APGA 0.784 0.693–0.875
FIB-4 0.726 0.629–0.823
APRI 0.727 0.636–0.818
doi:10.1371/journal.pone.0023077.t003
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The PAPAS index was based on five common clinical
parameters: age, ALP, AST, AFP and platelet count. All 5
parameters had been shown in previous studies to be associated
with significant fibrosis in CHB [20,21,24]. Age is a valuable
predictor since progression of fibrosis in CHB is time-dependent
[34,35]. Increased fibrosis results in a reduced clearance of AST
and hence an elevated serum level [36]. A low platelet count has
also been associated with advanced liver fibrosis through the
altered production of thrombopoietin [37]. The addition of extra
variables other than these five parameters did not further improve
the accuracy of the current predictive model. Both ALT and HBV
DNA levels, known to fluctuate during the natural history of CHB
[38], were not included in the PAPAS index. While previous
studies had shown several markers, including hyaluronic acid, a-2
macroglobulin and apolipoprotein A1, to have a predictive value
in CHB, these markers may not be available in the routine
evaluation of chronic liver diseases. Using them in predictive
models might hinder their widespread use [18,20,25,26].
Many predictive models in previous studies [15,21,22,25] were
created using stepwise regression, a prediction method based on
identified independent variables to achieve a best-fit model [39].
While commonly used, stepwise regression had been shown to be
prone to errors of sampling, measurement and specification [40].
Moreover, a rigid setup in computer programming and a
misreading in the order of importance of various predictor
variables could result in serious misinterpretation of results [41].
L1 regularized regression adopted in the present study identifies
the order in which variables enter or leave the created model,
allowing more flexibility in finding a regularized fit with any given
number of parameters [42], and has been increasingly used in the
design of predictive models in different clinical studies
[24,43,44,45].
The current study has certain limitations. Our study only had
Chinese CHB patients. Given that 67.6% of patients in our study
cohort had limited fibrosis, the study would be biased towards
having a high negative predictive value. The PAPAS index was
not statistically superior to both the APGA index and FIB-4 index,
probably due to the limited number of patients in our present
study. Hence, external validation of the PAPAS index with an
independent validation cohort would be important before
considering widespread use. Body mass index and cholesterol
levels were not available in our study, thus we were unable to
compare our model with other predictive indices, including the
Forns index [15,21]. Given that the current patient cohort consists
of patients with potential to be recruited into drug trials, there
would be fewer patients with an inactive disease and low viral load.
Our predictive model might not be applicable to this group of
patients. However, our cohort included patients with HBV DNA
$2000 IU/mL, which is the threshold level suggested by CHB
guidelines in commencing treatment. Due to the small number of
patients with histologic cirrhosis, we were unable to create a
predictive model for cirrhosis, which would have less measurement
and observer error in detection if possible [11]. Similar to previous
models based on CHB patients [20,21], the PAPAS index did not
achieve a high positive predictive value. Therefore, the PAPAS
index will be best applicable in excluding patients with
insignificant fibrosis in whom treatment may not be necessary at
the time of measurement. For patients with the score above the
optimal cut-off level of 1.662, the decision of treatment should be
considered in conjunction with other disease parameters or viral
markers.
A possible method to improve the diagnostic accuracy of
predictive models is to combine the available clinical parameters
with imaging or transient elastography. The former had been
attempted by including the spleen size on imaging, with a high
positive predictive value for cirrhosis obtained [23]. The accuracy
of transient elastography in CHB is hindered whenever the ALT
levels are elevated [46], but this could be improved by combining
transient elastography with a non-invasive predictive model like
the Forns index [47]. The sequential use of non-invasive markers is
also another option [48], although such studies are lacking in CHB
patients.
In conclusion, the PAPAS index, a newly-designed predictive
model using routinely-available clinical parameters, can accurately
predict significant liver fibrosis in CHB patients, and potentially
reduce the need for liver biopsies. Further studies would be needed
to validate this model and compare it with other non-invasive
models of fibrosis in CHB.
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Table 4. Sensitivity, specificity, predictive values and likelihood ratios of scores according to different cut-offs for predicting
significant fibrosis.
Optimal cut-off Sensitivity Specificity PPV NPV LR+ LR2
PAPAS 1.662 73.3% 78.2% 56.4% 88.4% 3.365 0.341
APGA 6.687 16.9% 98.1% 81.3% 71.0% 9.027 0.847
FIB-4 1.45 51.9% 74.4% 49.4% 76.3% 2.028 0.646
3.25 9.09% 99.4% 87.5% 69.4% 14.670 0.915
APRI 0.5 89.6% 40.6% 42.1% 89.0% 1.509 0.256
1.5 29.9% 88.1% 54.8% 72.3% 2.516 0.796
PPV =positive predictive value.
NPV= negative predictive value.
LR+=positive likelihood ratio.
LR2=negative likelihood ratio.
doi:10.1371/journal.pone.0023077.t004
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